RecruitingGonorrheaChlamydiaSyphilis
Doxycycline Prophylaxis for Prevention of Sexually Transmitted Infections
Eligible age
13–29 yrs
Accepts
Women
Locations
12 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The goal of this open-label, randomized trial is to assess the efficacy of doxycycline prophylaxis in reducing incidences of bacterial sexually transmitted infections (STIs) among adolescent and young adult females while also evaluating acceptability and antimicrobial resistance in order to inform public health policy.
Sponsor: Westat
You may qualify if…
- ✓ Age 13-29 years, inclusive;
- ✓ Self-reports GC, CT, and/or early syphilis diagnosis in the 12 months prior to screening;
- ✓ Self-reports condomless (oral, vaginal, and/or anal) intercourse at least once in the 30 days prior to screening
- ✓ Is at least 45 kilograms (99.2 pounds) in weight
- ✓ Fluent in English (able to read, speak, and understand English);
- ✓ Willing to undergo all required study procedures; and
- ✓ Willing to provide written informed consent to participate in the study.
You may not qualify if…
- ✕ Is male;
- ✕ Is pregnant, breastfeeding, or planning to become pregnant in the next 12 months;
- ✕ Documented history of tetracycline allergy or self-reports an allergy to tetracyclines;
- ✕ Current or anticipated use of a medication (e.g., barbiturates, phenytoin, lithium, carbamazepine, systemic retinoids, warfarin) with a contraindicated interaction to doxycycline ;
- ✕ Current or planned use of doxycycline for a prolonged period (\> 2 weeks) in the 30 days prior to enrollment, including current prescription for doxycycline for STI prophylaxis;
- ✕ Prolonged antibiotic use (\> 2 weeks) within the last 30 days prior to enrollment;
- ✕ Co-enrollment in any other concurrent interventional research or studies that may interfere with this study, such as an STI prevention trial, unless approved by Protocol Team in writing;
- ✕ Does not have consistent access (or anticipated weekly access for 52 weeks of survey completion) to smartphone that can access the HMP app; or
Where it's recruiting
California
Los Angeles · San Francisco
District of Columbia
Washington D.C.
Florida
Tampa
Georgia
Atlanta
Illinois
Chicago
Louisiana
New Orleans
Maryland
Baltimore
New York
New York
North Carolina
Chapel Hill
Pennsylvania
Philadelphia
Tennessee
Memphis
Texas
Houston
Source: ClinicalTrials.gov · NCT06738407 · last updated 2026-05-15